Living Pharma Adds Noted Oncologist to its Advisory Board
Baltimore, MD, November 1, 2016 – Living Pharma, Inc. announced today that it has added Aaron P. Rapoport, MD, to its advisory board. Dr. Rapoport is a professor in the Department of Medicine, the Gary Jobson Professor of Medical Oncology and the Director of the Blood and Marrow Stem Cell Transplant Program in the Greenebaum Cancer Center, at the University of Maryland School of Medicine and Medical Center.
Dr. Rapoport is a board-certified hematologist and stem cell transplant (SCT) physician with more than 25 years of experience in the care of patients with hematopoietic neoplasms and benign hematologic disorders. He also conducts translational research that focuses on the use of co-stimulated and genetically modified autologous T cells and vaccines to enhance immune recovery after autologous stem cell transplants for hematologic malignancies.
In 2012, Dr. Rapoport was named the inaugural Gary Jobson Professor of Medical Oncology at the University of Maryland School of Medicine. He was also named a “Top Doc” by Baltimore Magazine in 2011, 2012, 2013, 2014, 2015 and 2016.
“We are pleased that Dr. Rapoport has agreed to serve on Living Pharma’s advisory board. His experience in translating new T-cell therapies to treat leukemia and lymphoma will prove invaluable to our clinical development efforts. We look forward to working with Dr. Rapoport to bring much needed cures to patients suffering from hematologic cancer. ” said Dr. Eduardo Davila, founder and chief science officer of Living Pharma.
About Living Pharma
Living Pharma develops Personalized CAR T Cell Therapy™. We are focused on developing therapeutic immuno-oncology products optimized for each individual patient. Our universal Anti-Tag Chimeric Antigen Receptor (AT-CAR™) T cells can be tailored to the individual patient’s cancer and disease phenotype. The company is headquartered in Baltimore, MD. For more information, visit http://www.livingpharma.com.